Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer

被引:29
作者
Imawari, Yoshimi [1 ,2 ]
Mimoto, Rei [2 ]
Hirooka, Shinichi [3 ]
Morikawa, Toshiaki [2 ]
Takeyama, Hiroshi [2 ]
Yoshida, Kiyotsugu [1 ]
机构
[1] Jikei Univ, Dept Biochem, Sch Med, Tokyo, Japan
[2] Jikei Univ, Dept Surg, Sch Med, Tokyo, Japan
[3] Jikei Univ, Dept Pathol, Sch Med, Tokyo, Japan
关键词
breast cancer; cyclin-dependent kinase 14; dual-specificity tyrosine-regulated kinase 2; invasion; proliferation; EPITHELIAL-MESENCHYMAL-TRANSITION; DYRK2; EXPRESSION; PROSTATE-CANCER; DNA-DAMAGE; PFTK1; PHOSPHORYLATION; CHEMOTHERAPY; SUPPRESSOR; MARKER; OVEREXPRESSION;
D O I
10.1111/cas.13459
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor progression is the main cause of death in patients with breast cancer. Accumulating evidence suggests that dual-specificity tyrosine-regulated kinase 2 (DYRK2) functions as a tumor suppressor by regulating cell survival, differentiation, proliferation and apoptosis. However, little is known about the mechanisms of transcriptional regulation by DYRK2 in cancer progression, particularly with respect to cancer proliferation and invasion. Here, using a comprehensive expression profiling approach, we show that cyclin-dependent kinase 14 (CDK14) is a target of DYRK2. We found that reduced DYRK2 expression increases CDK14 expression, which promotes cancer cell proliferation and invasion invitro, in addition to tumorigenicity invivo. CDK14 and DYRK2 expression inversely correlated in human breast cancer tissues. We further identified androgen receptor (AR) as a candidate of DYRK2-dependent transcription factors regulating CDK14. Taken together, our findings suggest a mechanism by which DYRK2 controls CDK14 expression to regulate tumor cell proliferation and invasion in breast cancer. Targeting of this pathway may be a promising therapeutic strategy for treating breast cancer.
引用
收藏
页码:363 / 372
页数:10
相关论文
共 30 条
[11]   Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer [J].
Mimoto, R. ;
Imawari, Y. ;
Hirooka, S. ;
Takeyama, H. ;
Yoshida, K. .
ONCOGENE, 2017, 36 (13) :1862-1872
[12]   Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR [J].
Mimoto, Rei ;
Nihira, Naoe T. ;
Hirooka, Shinichi ;
Takeyama, Hiroshi ;
Yoshida, Kiyotsugu .
CANCER LETTERS, 2017, 384 :27-38
[13]   DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail [J].
Mimoto, Rei ;
Taira, Naoe ;
Takahashi, Hiroyuki ;
Yamaguchi, Tomoko ;
Okabe, Masataka ;
Uchida, Ken ;
Miki, Yoshio ;
Yoshida, Kiyotsugu .
CANCER LETTERS, 2013, 339 (02) :214-225
[14]   Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma [J].
Miyagaki, H. ;
Yamasaki, M. ;
Miyata, H. ;
Takahashi, T. ;
Kurokawa, Y. ;
Nakajima, K. ;
Takiguchi, S. ;
Fujiwara, Y. ;
Ishii, H. ;
Tanaka, F. ;
Mori, M. ;
Doki, Y. .
BRITISH JOURNAL OF CANCER, 2012, 106 (05) :947-954
[15]   Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy [J].
Nomura, Shunichiro ;
Suzuki, Yasutomo ;
Takahashi, Ryo ;
Terasaki, Mika ;
Kimata, Ryoji ;
Terasaki, Yasuhiro ;
Hamasaki, Tsutomu ;
Kimura, Go ;
Shimizu, Akira ;
Kondo, Yukihiro .
BMC UROLOGY, 2015, 15
[16]   Expression of androgen receptors in primary breast cancer [J].
Park, S. ;
Koo, J. ;
Park, H. S. ;
Kim, J. -H. ;
Choi, S. -Y. ;
Lee, J. H. ;
Park, B. -W. ;
Lee, K. S. .
ANNALS OF ONCOLOGY, 2010, 21 (03) :488-492
[17]   The MAPPER2 Database: a multi-genome catalog of putative transcription factor binding sites [J].
Riva, Alberto .
NUCLEIC ACIDS RESEARCH, 2012, 40 (D1) :D155-D161
[18]   Functional characterization of human PFTK1 as a cyclin-dependent kinase [J].
Shu, Fang ;
Lv, Shun ;
Qin, Yan ;
Ma, Xinlu ;
Wang, Xin ;
Peng, Xiaozhong ;
Luo, Ying ;
Xu, Bing-e ;
Sun, Xiaoqing ;
Wu, Jun .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (22) :9248-9253
[19]   DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage [J].
Taira, Naoe ;
Nihira, Keishi ;
Yamaguchi, Tomoko ;
Miki, Yoshio ;
Yoshida, Kiyotsugu .
MOLECULAR CELL, 2007, 25 (05) :725-738
[20]   DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells [J].
Taira, Naoe ;
Mimoto, Rei ;
Kurata, Morito ;
Yamaguchi, Tomoko ;
Kitagawa, Masanobu ;
Miki, Yoshio ;
Yoshida, Kiyotsugu .
JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (03) :859-872